A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Open-angle Glaucoma Eye Diseases Glaucoma Glaucoma, Open-Angle Ocular Hypertension

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

United States Investigative Sites

Fort Worth, Texas, 76134, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

18 years of age or older
Diagnosis of open-angle glaucoma
Other protocol-defined inclusion criteria may apply

Exclusion criteria

Under 18
Pregnant
Other protocol-defined exclusion criteria may apply

Treatment and study plan

Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension

Drug

One drop twice daily in each study eye for six months

Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension

Drug

One drop twice daily in each study eye for six months

Other names: AZOPT

Timolol 5 mg/ml eye drops, solution

Drug

One drop twice daily in each study eye for six months

Primary outcomes

Mean intra-ocular pressure (IOP)

Sponsors and collaborators

Lead sponsor

Alcon Research

Industry

Registry information

Important dates

Study start: 2005
Primary completion: 2007
Study completion: 2007
First posted: Apr 13, 2006
Registry last updated: Nov 18, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed